Hunan Jingfeng Pharmaceutical Co FCF Conversion
The FCF Conversion Rate (FCF/EBITDA) of Hunan Jingfeng Pharmaceutical Co (000908.SZ) as of Oct 10, 2026 is -67.69 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -4.55 % — a change of 1,387.23% (lower).
Get this data via API
Financial Data API
FCF Conversion
-67.69 %
YoY
1,387.23%
Last updated:
The Hunan Jingfeng Pharmaceutical Co FCF Conversion history
3 Years
10 Years
25 Years
Max
| YEAR | FCF Conversion | YoY |
|---|---|---|
| -67.69 % | +1,387.23% | |
| -4.55 % | -56.40% | |
| -10.44 % | -88.34% | |
| -89.55 % | +70.97% | |
| -52.37 % | -252.19% | |
| 34.41 % | +292.17% | |
| 8.78 % | -90.88% | |
| 96.26 % | -202.93% | |
| -93.52 % | +32.23% | |
| -70.72 % | +75.18% | |
| -40.37 % | -196.22% | |
| 41.96 % | — |
Hunan Jingfeng Pharmaceutical Co Stock analysis
Frequently Asked Questions about Hunan Jingfeng Pharmaceutical Co stock
FCF Conversion Rate (FCF/EBITDA) of Hunan Jingfeng Pharmaceutical Co is -67.69 % in 2025.
FCF Conversion Rate (FCF/EBITDA) of Hunan Jingfeng Pharmaceutical Co changed from -4.55 % to -67.69 %, representing a 1,387.23% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Hunan Jingfeng Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.
FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.
A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Hunan Jingfeng Pharmaceutical Co with sector peers and the industry average to assess whether it is attractive.
To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).
Cash Flow — Hunan Jingfeng Pharmaceutical Co
All Key Metrics — Hunan Jingfeng Pharmaceutical Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth